The global diabetic retinopathy market size is expected to reach USD by 14.95 Billion 2028 at a CAGR of 7.10%, according to a new report by Reports and Data. Rising prevalence of chronic conditions such as diabetes, increasing cases of diabetic retinopathy among diabetic patients, and growing preferences for technologically advanced and minimally invasive procedures are among the major factors responsible for the growth of the global diabetic retinopathy market in the upcoming years. Booming geriatric population worldwide and their growing susceptibility to chronic diseases such as diabetes, cardiovascular disorders, and sleep disorders further boost market growth to a significant extent.
Diabetic retinopathy is a severe medical condition in which diabetes affects the eyes. The principal cause of diabetic retinopathy is damage to the blood vessels of the light-sensitive tissue of the retina. The most common symptoms of this condition include blurred vision, fluctuating vision, dark or empty areas in the vision, impaired color vision, and vision loss. Excessive amount of sugar in blood leads to the blockage of the tiny blood vessels of the retina and hamper blood supply. Mild-to-moderate cases of diabetic retinopathy may be treated with the help of effective diabetes management; however, advanced cases require laser treatment or surgical procedures.
Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.reportsanddata.com/sample-enquiry-form/1484
Some Key Highlights in the Report:
- Non-proliferative diabetic retinopathy segment is projected to register the highest CAGR of 7.5% over the forecast period. Rising prevalence of non-proliferative diabetic retinopathy among diabetic patients is one of the most vital factors driving this segment’s growth.
- On the basis of management, the anti-VEGF segment dominated tin terms of revenue in 2020. The segment is expected to maintain its dominance throughout the forecast period, owing to increasing applications of anti-VEGF drugs including Eylea, Lucentis, Avastin, and Macugen in the treatment of mild-to-moderate cases of diabetic retinopathy is one of the key factors accountable for the growth of this segment.
- Among the various distribution channels, the hospitals segment held the largest revenue share in the global diabetic retinopathy market in 2020. Increasing availability of diagnostic instruments in hospitals and pharmacies worldwide and growing number of treatment procedures for diabetic retinopathy bolster the growth of this segment.
- The North America diabetic retinopathy market is the most dominant regional market in terms of revenue. Growing prevalence of diabetes, increasing use of anti-VEGF drugs including Avastin, Eylea, and Lucentis for diabetic retinopathy, rising patient awareness, and the presence of state-of-the-art healthcare infrastructure in North America are the primary factors accountable for the regional market growth. The Asia Pacific market is the fastest-growing regional market and is expected to display a robust CAGR of 8.3% over the forecast period.
Competitive Landscape:
The report also focuses on details of each market player including its global position, financial standing, revenue generation, company overview, product & service portfolio. The Diabetic Retinopathy market is extremely competitive and consists of several key players at regional and global level. Key players are focused on adopting various strategies such as new product launches, mergers and acquisitions, investments in R&D, partnerships, joint ventures and collaborations to strengthen their market position and enhance product portfolio.
Leading companies operating in the market are:
- Bayer AG
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd.
- Regeneron Pharmaceuticals Inc.
- Novartis AG
- Valeant Pharmaceuticals International Inc.
- Abbott Laboratories Ltd.
- Alimera Sciences Inc.
- AmPio Pharmaceuticals Inc.
- Bausch & Lomb Inc.
- Boehringer Ingelheim GmbH
- iCo Therapeutics Inc.
- Lupin Ltd.
- PAREXEL International Corp.
- Quark Pharmaceuticals Inc.
- Thrombogenic NV
- Vitreoretinal Technologies Inc.
Inquiry Before Buying @ https://www.reportsanddata.com/inquiry-before-buying/1484
The report also offers detailed insights about market segmentation based on type, application and regional bifurcation:
Diabetic Retinopathy Market Segmentation:
Type Outlook:
- Proliferative diabetic retinopathy
- Non-proliferative diabetic retinopathy
- Mild
- Moderate
- Severe
Management Outlook:
- Anti-VEGF
- Intraocular steroid injection
- Laser surgery
- Vitrectomy
Distribution Channel Outlook:
- Eye clinics
- Hospital and pharmacies
- Ambulatory surgical centers
- Other
Geographic Segment Covered in the Report:
The Diabetic Retinopathy report provides information about the market area, which is further subdivided into sub-regions and countries/regions. In addition to the market share in each country and sub-region, this chapter of this report also contains information on profit opportunities. This chapter of the report mentions the market share and growth rate of each region, country, and sub-region during the estimated period.
• North America (the USA and Canada)
• Europe (UK, Germany, France, and the rest of Europe)
• Asia Pacific (China, Japan, India, and the rest of the Asia Pacific region)
• Latin America (Brazil, Mexico, and the rest of Latin America)
• the Middle East and Africa (GCC and the rest of the Middle East and Africa)
Browse Full Report Description with Research Methodology, Table of Content, and Infographics @ https://www.reportsanddata.com/report-detail/diabetic-retinopathy-market
Key market aspects are illuminated in the report:
- Executive Summary: It covers a summary of the most vital studies, the Global Diabetic Retinopathy market increasing rate, modest circumstances, market trends, drivers and problems as well as macroscopic pointers.
- Study Analysis: Covers major companies, vital market segments, the scope of the products offered in the Global Diabetic Retinopathy market, the years measured, and the study points.
- Company Profile: Each Firm well-defined in this segment is screened based on a products, value, SWOT analysis, their ability and other significant features.
- Manufacture by Region: This Global Diabetic Retinopathy report offers data on imports and exports, sales, production and key companies in all studied regional markets.
Request customization of the report @ https://www.reportsanddata.com/request-customization-form/1484
Thank you for reading the report. Kindly note that we also offer customized reports according to the client’s requirements. Contact us to know more about the customization feature and our team will provide you with the best-customized report.
Explore More Industry Research by Reports and Data:
Osteoarthritis Treatment Market @ https://www.biospace.com/article/osteoarthritis-treatment-market-with-high-cagr-in-future-with-industry-demand-and-focusing-key-players-by-2030/
Warts Treatment Market @ https://www.biospace.com/article/warts-treatment-market-expected-development-on-the-basis-of-study-of-key-players-research-growth-predictions-and-forecast-2030/
Wilms Tumor Market @ https://www.biospace.com/article/wilms-tumor-market-revenue-major-players-consumer-trends-analysis-and-forecast-till-2030/
Hypokalemia Market @ https://www.biospace.com/article/hypokalemia-market-size-key-player-revenue-swot-pest-and-porter-s-analysis-for-2022-2030/
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, TouchPoints, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provide our clients with the ability to secure an edge over their respective competitors.
Contact Us:
John W
Head of Business Development
Reports And Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: [email protected]
LinkedIn | Twitter | Blogs